Introduction. Sleep disturbance is a frequent complaint of patients suffering from arterial hypertension (AH) for a long time. A hidden and uncontrolled increase in blood pressure (BP) makes the course of physiological processes more difficult, disrupts the regulation of biological rhythms, and increases the risk of cardiovascular complications even with a short duration of AH. At the same time, chronic sleep disorders contribute to the development of hypertension, defining the role of a new socially significant risk factor. An important role in the pathogenesis of insomnia is played by a deficiency in melatonin (MT) synthesis, which negatively affects the cardiovascular system (CVS). Aim. The aim of the paper was to study the features of central and vascular hemodynamics in patients with the 1st degree AH and to evaluate the clinical effectiveness of antihypertensive therapy with synthetic analog of prolonged-release MT at the onset of the disease. Methods. Instrumental examination included registration of an electrocardiogram, office measurement of blood pressure with an automatic tonometer, non-invasive automatic blood pressure monitoring for 24 hours. The severity of insomnia was assessed by somnological questionnaires. Representatives of the 1st group (n = 34) took monotherapy with the ACE inhibitor ramipril, participants of the 2nd group (n = 33) took the ACE inhibitor ramipril in combination with a synthetic analogue of melatonin. Results. The results of a randomized open prospective study including 78 participants reveal the activity of the renin-angiotensin-aldosterone system (RAAS), hypersympathicotonia at night and desynchronosis due to a possible deficiency in the MT secretion. Pharmacological antihypertensive therapy with the addition of prolonged release MT analog was accompanied by a significant improvement in the clinical condition of hypertensive patients. Positive dynamics of indicators of systemic hemodynamics and functional arterial parameters of stiffness was noted. Conclusion. The article describes the probable benefits of melatonin as part of combination antihypertensive therapy in patients with early-stage hypertension and insomnia. Additional introduction of MT at the onset of the AN as a physiological regulator of circadian biological rhythms is substantiated.
References
1.
Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6).
2.
Hermida RC, Ayala DE, Fernandez JR, Portaluppi F, Fabbian F, Smolensky MH. Circadian Rhythms in Blood Pressure Regulation and Optimization of Hypertension Treatment With ACE Inhibitor and ARB Medications. American Journal of Hypertension. 2011;24(4):383–91.
3.
Osadchuk M, Vasil`eva IN, Mironova E, Khudarova AA, Korzhenkov N. Corrective effect of angiotensin-converting enzyme inhibitors on the daily profile of blood pressure and somnological characteristics in elderly patients with combined cardiac pathology. Medical news of the North Caucasus. 2019;14(3).
4.
Walczak-Gałęzewska M, Szulińska M, Miller-Kasprzak E, Pupek-Musialik D, Bogdański P. The effect of nebivolol and ramipril on selected biochemical parameters, arterial stiffness, and circadian profile of blood pressure in young men with primary hypertension. Medicine. 2018;97(30):e11717.
5.
Imai Y, Kuba K, Neely GG, Yaghubian-Malhami R, Perkmann T, van Loo G, et al. Identification of Oxidative Stress and Toll-like Receptor 4 Signaling as a Key Pathway of Acute Lung Injury. Cell. 2008;133(2):235–49.
6.
Ahmadi Z, Ashrafizadeh M. Melatonin as a potential modulator of Nrf2. Fundamental & Clinical Pharmacology. 2020;34(1):11–9.
7.
Reiter RJ, Ma Q, Sharma R. Melatonin in Mitochondria: Mitigating Clear and Present Dangers. Physiology. 2020;35(2):86–95.
8.
Tsvetkova ES, Romantsova TI, Poluektov MG, Runova GE, Glinkina IV, Fadeev VV. The importance of melatonin in the regulation of metabolism, eating behavior, sleep, and the prospects for the use of melatonin drugs for obesity treatment. Obesity and metabolism. 18(2):112–24.
9.
Katz A, Lemoine, Wade, Nir, Zisapel. Efficacy and safety of prolonged-release melatonin for insomnia in middle-aged and elderly patients with hypertension: a combined analysis of controlled clinical trials. Integrated Blood Pressure Control. :9.
10.
NICHOLS W. Clinical measurement of arterial stiffness obtained from noninvasive pressure waveforms. American Journal of Hypertension. 2005;18:3–10.
11.
Levy BI, Ambrosio G, Pries AR, Struijker-Boudier HAJ. Microcirculation in Hypertension. Circulation. 2001;104(6):735–40.
12.
Kobalava ZhD, Kotovskaya YuV, Bogomaz AV. NEW METHODS OF ASSESSMENT OF SUBCLINICAL CHANGES IN THE CARDIOVASCULAR SYSTEM IN ARTERIAL HYPERTENSION. Rational Pharmacotherapy in Cardiology. 12(3):317–24.
13.
Karoli NA, Zarmanbetova OT, Rebrov AP. AMBULATORY ARTERIAL STIFFNESS MONITORING IN PATIENTS WITH ASTHMA. The Russian Archives of Internal Medicine. 9(4):301–7.
14.
Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. 2021;42(34):3227–337.
15.
Vasyuk YuA, Ivanova SV, Shkolnik EL, Kotovskaya YuV, Milyagin VA, Oleynikov VE, et al. Consensus of Russian experts on the evaluation of arterial stiffness in clinical practice. Cardiovascular Therapy and Prevention. 15(2):4–19.
16.
Hageman S, Pennells L, Ojeda F, Kaptoge S, Kuulasmaa K, et al. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. European Heart Journal. 2021;42(25):2439–54.
17.
Bjorøy I, Jørgensen VA, Pallesen S, Bjorvatn B. The Prevalence of Insomnia Subtypes in Relation to Demographic Characteristics, Anxiety, Depression, Alcohol Consumption and Use of Hypnotics. Frontiers in Psychology. 11.
18.
Zhang R, Wang X, Ni L, Di X, Ma B, Niu S, et al. COVID-19: Melatonin as a potential adjuvant treatment. Life Sciences. 2020;250:117583.
19.
Martinovich G, Cherenkevich S. Oxidationreduction processes in cells. 2008.
20.
Tordjman S, Chokron S, Delorme R, Charrier A, Bellissant E, Jaafari N, et al. Melatonin: Pharmacology, Functions and Therapeutic Benefits. Current Neuropharmacology. 2017;15(3):434–43.
21.
Reiter RJ, Mayo JC, Tan D, Sainz RM, Alatorre‐Jimenez M, Qin L. Melatonin as an antioxidant: under promises but over delivers. Journal of Pineal Research. 2016;61(3):253–78.
22.
Lerner AB, Case JD, Takahashi Y, Lee TH, Mori W. ISOLATION OF MELATONIN, THE PINEAL GLAND FACTOR THAT LIGHTENS MELANOCYTES1. Journal of the American Chemical Society. 1958;80(10):2587–2587.
23.
McCord CP, Allen FP. Evidences associating pineal gland function with alterations in pigmentation. Journal of Experimental Zoology. 1917;23(1):207–24.
24.
Antonov YeV, Alexandrovich YuV, Seryapina AA, Klimov LO, Markel AL. Stress and arterial hypertension: ISIAH rat strain. Vavilov Journal of Genetics and Breeding. 19(4):455.
25.
Strygin KN, Poluektov MG. INSOMNIA. Medical Council. (1S):52–8.
26.
Osadchuk M, Vasilieva I, Trushin M. Gender aspects of cardiovascular system functional status in senile patients with hypertension. Online J Health Allied Scs. 2019;18(4).
27.
Zisapel N. New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation. British Journal of Pharmacology. 2018;175(16):3190–9.
28.
Hoevenaar-Blom MP, Spijkerman AMW, Kromhout D, van den Berg JF, Verschuren WMM. Sleep Duration and Sleep Quality in Relation to 12-Year Cardiovascular Disease Incidence: The MORGEN Study. Sleep. 2011;34(11):1487–92.
29.
Ostroumova TM, Parfenov VA, Ostroumova OD, Kochetkov AI. Hypertension and insomnia. Terapevticheskii arkhiv. 92(1):69–75.
30.
Knutson KL, Spiegel K, Penev P, Van Cauter E. The metabolic consequences of sleep deprivation. Sleep Medicine Reviews. 2007;11(3):163–78.
31.
Latshang TD, Tardent RPM, Furian M, Flueck D, Segitz SD, Mueller-Mottet S, et al. Sleep and breathing disturbances in patients with chronic obstructive pulmonary disease traveling to altitude: a randomized trial. Sleep. 2019;42(1).
32.
Javaheri S, Redline S. Insomnia and Risk of Cardiovascular Disease. Chest. 2017;152(2):435–44.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
